Ambrosia Bio raises $100M for oral GLP-1 trial

The funding will support clinical trials for the company's oral weight loss drug candidate.

Mar. 31, 2026 at 6:18pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray image revealing the intricate internal structure of a small medication capsule, glowing against a dark background and conceptually representing the innovation of an oral GLP-1 weight loss treatment.Ambrosia's oral GLP-1 drug candidate could provide a more convenient alternative to injectable weight loss medications.Boulder Today

Ambrosia Biosciences, a Colorado-based biotech company, has closed a $100 million Series B funding round to advance clinical trials for its oral small molecule GLP-1 weight loss drug candidate.

Why it matters

The development of an oral GLP-1 medication could provide a more convenient alternative to injectable GLP-1 drugs currently on the market for weight management, potentially expanding access and improving patient adherence.

The details

Ambrosia's oral GLP-1 drug candidate is designed to mimic the effects of the naturally occurring glucagon-like peptide-1 (GLP-1) hormone, which plays a key role in regulating blood sugar levels and appetite. The new funding will allow the company to progress the drug through late-stage clinical trials.

  • Ambrosia Biosciences closed the $100 million Series B funding round on March 31, 2026.

The players

Ambrosia Biosciences

A Colorado-based biotech company developing an oral small molecule GLP-1 weight loss drug candidate.

Got photos? Submit your photos here. ›

What’s next

The company plans to use the Series B funding to advance its oral GLP-1 drug candidate through late-stage clinical trials, with the goal of eventually seeking regulatory approval.

The takeaway

The development of an effective oral GLP-1 medication could significantly improve weight management options for patients, providing a more convenient alternative to current injectable therapies.